Aptose Announces Results from Special Meeting of Shareholders
05 Septiembre 2024 - 3:15PM
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO,
TSX: APS), a clinical-stage precision oncology company developing
tuspetinib, a highly differentiated oral kinase inhibitor for the
treatment of patients with acute myeloid leukemia (AML), announced
the voting results from its special meeting of shareholders held
today, September 5, 2024 (the “Meeting”).
A total of 6,052,460 common shares of the
Company (the "Shares"), representing 33.42% of the issued and
outstanding Shares were voted at the Meeting.
The proposals put forward before the Company's
shareholders for consideration and approval, as set out in the
Company's definitive proxy statement dated July 11, 2024 (the
"Proxy Statement"), were approved by the requisite number of votes
cast at the Meeting, as further detailed below:
- Proposal No. 1 – passing a
resolution, the full text of which is set forth in the Proxy
Statement, approving the issuance of common shares of the
Corporation underlying certain warrants pursuant to Nasdaq Listing
Rules; and
- Proposal No. 2 – passing a
resolution, the full text of which is set forth in the Proxy
Statement, approving one or more adjournments of the Meeting, if
necessary or appropriate, if a quorum is present, to permit further
solicitation of proxies if there are not sufficient votes at the
time of the Meeting to approve Proposal No. 1.
Please refer to the Company’s Proxy Statement
available on SEDAR+ at www.sedarplus.ca or EDGAR
https://www.sec.gov/edgar.shtml for more details on the matters
covered at the Meeting. Final voting results on all matters voted
on at the Meeting will also be filed on SEDAR+ and EDGAR.
The detailed results of the vote at the Meeting
are set out below:
|
APTOSE BIOSCIENCES INC.ADJOURNED SPECIAL
MEETING OF SHAREHOLDERS HELD ON SEPTEMBER 5,
2024REPORT ON PROXIES |
|
MOTIONS |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
FOR |
AGAINST |
WITHHELD/ ABSTAIN |
RESTRICTED |
NON VOTE |
FOR |
AGAINST |
WITHHELD/ ABSTAIN |
Approval of Nasdaq 20% Issuance Proposal |
3,969,105* |
267,013 |
16,342 |
1,800,000 |
0 |
93.34% |
6.28% |
0.38% |
Multiple Adjournments |
5,873,779 |
138,958 |
39,722 |
|
1 |
97.05% |
2.30% |
0.66% |
* Excluding 1,800,000 shares held by
Insiders |
|
|
|
TOTAL SHAREHOLDERS VOTED BY
PROXY: |
47 |
|
|
|
|
TOTAL SHARES ISSUED &
OUTSTANDING: |
18,109,393 |
|
|
|
|
TOTAL SHARES
VOTED: |
6,052,460 |
|
|
|
|
TOTAL % OF SHARES
VOTED: |
33.42% |
|
|
|
|
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to developing precision medicines
addressing unmet medical needs in oncology, with an initial focus
on hematology. The Company's small molecule cancer therapeutics
pipeline includes products designed to provide single agent
efficacy and to enhance the efficacy of other anti-cancer therapies
and regimens without overlapping toxicities. The Company’s lead
clinical-stage compound tuspetinib (TUS), is an oral kinase
inhibitor that has demonstrated activity as a monotherapy and in
combination therapy in patients with relapsed or refractory acute
myeloid leukemia (AML) and is being developed as a frontline
triplet therapy in newly diagnosed AML. For more information,
please visit www.aptose.com.
For further information, please
contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
Aptose Biosciences (TSX:APS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Aptose Biosciences (TSX:APS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024